ELDN Share Price Performance
US$2.84
0.22 (8.40%)
Price US$2.84
Share PriceUS$2.84
Companies Like Eledon Pharmaceuticals (NASDAQ:ELDN) Are In A Position To Invest In Growth
May 07
Eledon Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ELDN Community Narratives
There are no narratives available yet.
Eledon Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.24
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Eledon Pharmaceuticals, Inc. Competitors
Snowflake Analysis
About ELDN
- Founded
- n/a
- Employees
- 31
- CEO
- WebsiteView website
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.2%
- 3 Months: 8.5%
- 1 Year: 17.7%
- Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›